clinical-trials.jpg

Roxadustat Trials 

Roxadustat Trials 

Our most advanced product candidate, roxadustat, is currently approved in China, Japan, and Chile for the treatment of anemia in CKD patients on dialysis and patients not on dialysis. Roxadustat is in global Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia (CIA). The goal of these clinical studies is to evaluate the safety and efficacy of the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor therapy for the treatment of anemia.

Anemia Associated with Myelodysplastic Syndromes

MATTERHORN Study – FG-4592-082, Phase 3, Anemia in myelodysplastic syndrome (MDS) patients

For more information on the study, please contact

Chemotherapy Induced Anemia

WHITNEY Study – FG-4592-092, Phase 2, Anemia in chemotherapy induced anemia (CIA) patients

For more information on the study, please contact